Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. DanCann Pharma AS's Total Stockholders Equity for the quarter that ended in Sep. 2025 was $1.11 Mil. DanCann Pharma AS's Total Assets for the quarter that ended in Sep. 2025 was $2.01 Mil.
Therefore, DanCann Pharma AS's Equity to Asset Ratio for the quarter that ended in Sep. 2025 was 0.55.
The historical rank and industry rank for DanCann Pharma AS's Equity-to-Asset or its related term are showing as below:
DCPXF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -6.96 Med: 0.8 Max: 0.9
Current: 0.55
During the past 7 years, the highest Equity to Asset Ratio of DanCann Pharma AS was 0.90. The lowest was -6.96. And the median was 0.80.
DCPXF's Equity-to-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.61
vs DCPXF: 0.55
DanCann Pharma AS (GREY:DCPXF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
DanCann Pharma AS Equity-to-Asset Related Terms
DanCann Pharma AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for DanCann Pharma AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DCPXF vs ZTS, UTHR, RGC: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DanCann Pharma AS Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where DanCann Pharma AS's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
DanCann Pharma AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DanCann Pharma AS (DCPXF) has a Equity-to-Asset of 0.55 as of Sep. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on DanCann Pharma AS and its competitors. This is 31% below median its historical median of 0.80.
Is DanCann Pharma AS's Equity-to-Asset too high?
DanCann Pharma AS's current Equity-to-Asset of 0.55 is 31% below median its 10-year median of 0.80. The Drug Manufacturers industry median Equity-to-Asset is 0.61. DanCann Pharma AS's value of 0.55 is 9.8% below this industry median. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's Equity-to-Asset compare to ZTS and UTHR?
DanCann Pharma AS's Equity-to-Asset of 0.55 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.61. DanCann Pharma AS's value of 0.55 is 9.8% below this benchmark. While the company's 10-year median is 0.80 vs. the industry median of 0.61, DanCann Pharma AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DanCann Pharma AS's current Equity-to-Asset of 0.55 is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on DanCann Pharma AS and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DanCann Pharma AS's current Equity-to-Asset is 0.55, which is 31% below median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current Equity-to-Asset of 0.55. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current Equity-to-Asset is 0.55, which is 31% below median its 10-year median of 0.80 and 9.8% below the Drug Manufacturers industry median of 0.61. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current Equity-to-Asset is 0.55 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DanCann Pharma AS (DCPXF) Overvalued in 2026?
Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued.
The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.
Key valuation signals for DCPXF:
Equity-to-Asset: 0.55 (31% below median its 10-year median of 0.80)
GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
Industry Position: 9.8% below the Drug Manufacturers median
No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score
Get the complete analysis for DCPXF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCPXF has been successfully added to your 
